2023-503233-22-00
已完成
1 期
Randomized, Open-label, Single-Dose, Two-treatment, Two-period, Cross-over, Pivotal Bioequivalence Study Comparing Amoxicilin/Clavulanic acid powder for oral suspension 600 mg/42.9 mg/5 mL to Augemntin ES 600 mg/42.9 mg/5 mL powder for oral suspension in Healthy Adult Male and Female Volunteers under Fed Conditions.
Tarchominskie Zaklady Farmaceutyczne Polfa S.A.1 个研究点 分布在 1 个国家目标入组 56 人2023年8月24日
概览
- 阶段
- 1 期
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- Tarchominskie Zaklady Farmaceutyczne Polfa S.A.
- 入组人数
- 56
- 试验地点
- 1
- 状态
- 已完成
- 最后更新
- 2年前
概览
简要总结
暂无简介。
研究者
Clinical Research Manager
Scientific
Tarchominskie Zaklady Farmaceutyczne Polfa S.A.
入排标准
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
未指定
研究点 (1)
Loading locations...
相似试验
招募中
不适用
A Randomized, Open-label, Single-Dose, 2-Treatment, 2-Way, 2-Period Crossover Study to Assess the Safety and the Pharmacokinetic Characteristics of Lodivikar tab. 5/40 mg in Healthy Adult Male SubjectsDiseases of the circulatory systemKCT0001252Hanlim Pharmaceutical32
已完成
不适用
Assessment of Safety and Pharmacokinetic Characteristics of CANDEAMLO Tablet 16/10mg in Healthy Adult Male SubjectsKCT0002205Shin Poong Pharm46
已完成
不适用
Prospective study in comparing the safety and the pharmacokinetics of Mosapride and Rebamipide having the effects on gastrointestinal diseases when administered as single drug or a complex in healthy korean male adultsDiseases of the digestive systemKCT0001123Ildong pharmaceutical30
进行中（未招募）
不适用
To evaluate the Bioequivalence of hypercholesterolemia formulation/hyperlipidemia formulation and hyperlipidemia forumlation/hypercholesterolemia formulation in Clinical phase 1 studyEndocrine, nutritional and metabolic diseaseKCT0001317Ildong pharmaceutical60
已完成
不适用
Pharmacokinetics of cilostazol controlled- and immediate-release (Pletal) tabletsKCT0002340Korea United Pharm30